BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Apax Partners Appoints Sharon Tetlow As Venture Partner To The Healthcare Investment Team


10/19/2005 5:11:55 PM

MENLO PARK, Calif., Oct. 26 /PRNewswire/ -- Funds advised by Apax Partners, one of the world's leading private equity groups, today announced the appointment of Sharon Tetlow as a Venture Partner on the firm's healthcare team.

"Sharon brings strong financial, capital markets and operational expertise that will bring immediate value to our portfolio companies as well as to our review of new investment opportunities," said Dr. Lori Rafield, Partner, who heads Apax Partners' U.S. Healthcare investment team. "Our investments range from early-stage companies to late-stage investments, including divestitures, late-stage growth equity investment opportunities and buyouts. We are known for providing operational support to our portfolio companies. Apax Partners is committed to providing resources to its investments in addition to capital. Sharon's deep operational experience fits perfectly with our philosophy of being a value-added investor."

"I am excited to join one of the most creative and successful teams in healthcare venture capital," said Ms. Tetlow.

Ms. Tetlow brings to Apax Partners nearly two decades of financial expertise at both public and private biotechnology companies. Prior to joining Apax Partners, Ms. Tetlow was chief financial officer at diaDexus, Inc., a privately held biotechnology company focused on the discovery, development, and commercialization of novel diagnostic products. At diaDexus, she was responsible for the company's financial strategy and capital markets activities.

During her tenure at diaDexus, Ms. Tetlow was instrumental in raising over $100 million in private equity in 2000, which, up to that time, was the largest single round raised by a private biotechnology company. She also managed shareholder relations, corporate public relations, facilities and information technology, and secured the company's largest diagnostic collaboration.

Before diaDexus, Ms. Tetlow was chief financial officer of two private biotech companies, Reprogen, Inc. and Terrapin Technologies, where she raised financings, closed corporate deals and oversaw all other financial operations. Prior to that, she was Corporate Treasurer and Director of Strategic Planning and Finance at Synergen, playing an instrumental role on the team that sold that company to Amgen. Before that, she served for several years in various strategic financial roles at biotechnology and pharmaceutical leaders Genentech Inc. and Eli Lilly and Company.

She graduated magna cum laude from the University of Delaware and holds an MBA from Stanford University. Ms. Tetlow is a member of Phi Beta Kappa.

About Apax Partners

Apax Partners is one of the world's leading private equity investment groups, operating across the United States, Europe, Israel and Japan. With over 30 years of direct investing experience, Apax Partners' Funds provides long-term equity financing to entrepreneurs to build and strengthen world- class companies. It pursues a balanced equity portfolio strategy, investing in companies at all stages of development from early stage to buy-out. Apax Partners' Funds invests in companies across its six chosen global sectors of: information technology; telecommunications; healthcare; media; financial services; retail; and consumer. Some of Apax Partners Funds' healthcare investments include Zymogenetics, Affymax, Novacea, Aerovance, ESP Pharmaceuticals, and Skinmedica.

Apax Partners manages and advises over $12 billion on behalf of leading institutional investors around the world. For more information, please visit http://www.apax.com/.

For more information: Contact: Laura Brightsen Apax Partners Marketing Director 212-419-2461 Jim Weiss WeissComm Partners Office: 415-362-5018

Apax Partners

CONTACT: Laura Brightsen, Marketing Director of Apax Partners,+1-212-419-2461; or Jim Weiss of WeissComm Partners, +1-415-362-5018, for ApaxPartners



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES